MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD		MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD		MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD		MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD	MEL-JUS Belvarafenib 400 Cobi 60mg	SO DOMG BID g QD
Relative Viability 1.00 0.75 0.50 0.25 0.00	The state of the s	RelativeViability 1.00 0.75 0.50 0.25 0.00	Relative Viability 1.00 0.75 0.50 0.25 0.00	RelativeViate 1.00	Dility Winding Company of the state of the	-1-	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3 -	IdativeViability 1.00 0.75 0.50 0.25 0.00 -3 -	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3 -	Relative Viability 1.00 0.75 0.50 0.25 0.00	Re de la constant de	Delative Viability 1.00 0.75 0.50 0.25 0.00	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -		Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -		RelativeViability 1.00	RelativeViability 1.00 0.75 0.50 0.25 0.00
-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD		-3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD		-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD	-1 -4 -3 panRAFi_Belvara MEL-JU Belvarafenib 40 Cobi 60mg	-2 -1 afenib uM JSO 400mg BID ng QD
HSA Excess 0.6 0.3 0.0 -0.6	HSA Excess 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	HSA Excess 0.6 0.3 0.0 -0.3 -0.6	HSA Excess 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	HSA Exc 0 0 0 0 0	HSA Excess 1.6 1.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0	-1-	HSA Excess 0.6 0.3 -0.3 -0.3 -0.6 -3-	HSA Excess 0.6 0.3 -0.3 -0.6 -0.6	HSA Excess 0.6 0.3 -0.3 -0.3 -0.6 -0.6	HSA Excess 0.6 0.3 -0.3 -0.6 -0.3 -0.6		HSA Excess 0.6 0.3 -0.3 -0.3 -0.6 -3-	HSA Excess 0.6 0.3 0.0 -0.3 -0.6 -0.6		HSA Excess 0.6 0.3 0.0 1.0 1.0 1.0 1.0 1.0 1.0	HSA Excess 0.6 0.3 -0.6 -0.3 -0.6 -0.6 -3 -		HSA Excess 0.6 0.3 -0.3 -0.3 -0.6 -3-	HSA Excess 0.6 0.3 0.0 -0.3 -0.6
-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD		-3 -2 -1 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD		-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	<u>-1</u>	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD	-1 -4 -3 panRAFi_Belvar MEL-JU Belvarafenib 40 Cobi 60mg	JSO HOOmg BID
Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Excess Mn Quipueulipueu	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 0.00 -0.25 -0.50	Bliss Exc 0 0 0 0 0 0 0 0 0 0 0 0 0	Dess Sess 1.50	-1	Bliss Excess 0.50 0.25 0.00 0.25 0.00 0.25 0.00 0.25 0.00 0.00	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -0.50 -3 -3 -3 -2 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.25 -0.25 -0.50 -3 -	-3 _2 _1 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.25 -0.25 -0.50 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 0.00 1.33 -3 -4	PanRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.25 -0.25 -0.50 -0.50 -0.50 -0.50 -0.7 -0.50 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.25 0.00 0.00 0.00 -0.25 -0.50 -0.50 -3 -	-4 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.25 -0.25 -0.50 -3 panRAFi_Belvar	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50
SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD		SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD		SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD		SK-MEL-2 Belvarafenib 200mg QD Cobi 60mg QD	SK-MEL- Belvarafenib 400 Cobi 60mg	.–2 00mg BID g QD
Relative Viability O.9 O.6 O.3 O.0 O.0	Who differential in the second of the second	RelativeViability 0.9 0.6 0.3 0.0	Wegitive Viability Relative Viability 0.9 0.6 0.3 0.0	RelativeViate RelativeViate 0.9 0.6 0.3 0.0	bility Willing William Will	-1- -2- -3-	Relative Viability -1 - 0.9	lativeViability 0.9 0.6 0.3 0.0 -3	RelativeViability	Relative Viability	Re	elative Viability 0.9 0.6 0.3 0.0 -3 -	Relative Viability		Relative Viability 0.9 0.6 0.3 0.0 -3	Relative Viability		RelativeViability 0.9 0.6 0.6 0.3 0.0 -3 -	RelativeViability 0.9 0.6 0.3 0.0
-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD		-3 -2 -1 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD		-3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	-1 -4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	-1	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 60mg QD	-1 -4 -3 panRAFi_Belvarar SK-MEL Belvarafenib 40 Cobi 60mg	-2 -1 afenib uM EL-2 400mg BID ng QD
HSA Excess -1- 0.4 0.0 -0.4	HSA Excess HSA Excess Winding -2 0.4 -0.4 WERITOR TO BE THE PROPERTY OF T	HSA Excess 0.4 0.0 -0.4	HSA Excess HSA Excess 0.4 0.0 -0.4 WEK! Copiumetinib um	-1- Win -23-	HSA Excess HSA Excess 0.4 0.0 0.0 -0.4	-3-	HSA Excess 0.4 Use of the second of the s	HSA Excess Who quiyaguiyaguiyaguiyaguiyaguiyaguiyaguiyag	HSA Excess Who discussed the first state of the fi	HSA Excess Wn qiringingingingingingingingingingingingingi		HSA Excess 0.4 0.0 -0.4 WE WE WITH THE PROPERTY OF THE PRO	HSA Excess 0.4 0.0 -0.4 WEK! COPIUME -2		HSA Excess 0.4	HSA Excess		HSA Excess 0.4	HSA Excess 0.4 0.0 -0.4
panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QQD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	-1 - 1	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD	-1 - -4	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	-1 -	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 60mg QD	panRAFi_Belvar SK-MEL Belvarafenib 40 Cobi 60mc	arafenib uM EL-2 400mg BID ng QD
Bliss Excess 0.5 0.0 -0.5	Bliss Excess Magina -2 0.0 0.5 0.5 0.7 Name of the service o	Bliss Excess 0.5 0.0 -0.5	Bliss Excess O.5 O.0 O.0 O.5 HEK! Cobimetriib ut	Bliss Exc	Bliss Excess -5	-2-	Bliss Excess 0.5 0.0 0.0 -0.5 -3	Bliss Excess 0.5 0.0 -0.5 -0.5 -3	Bliss Excess -0.5 Who directly a served as a served	Bliss Excess 0.5 0.0 -0.5 -0.5 -0.5		-1 - Bliss Excess 0.5	Bliss Excess -0.5 0.0 -0.5 -0.5 -3		Bliss Excess 0.5	Bliss Excess		Bliss Excess Who compared to the compared to	Bliss Excess
Belvarafenib 50mg QD Cobi 20mg QOD	Belvarafenib 100mg BID Cobi 20mg QOD .	Belvarafenib 200mg QD Cobi 20mg QOD .	Belvarafenib 400mg BID Cobi 20mg QOD .	Belvarafenib 50mg QD Cobi 20mg QD .	Belvarafenib 100mg BID Cobi 20mg QD	Belvarafenib 200mg QD Cobi 20mg QD .	Belvarafenib 400mg BID Cobi 20mg QD .	Belvarafenib 50mg QD Cobi 40mg QD	Belvarafenib 100mg BID Cobi 40mg QD		Belvarafenib 200mg QD Cobi 40mg QD	Belvarafenib 400mg BID Cobi 40mg QD		Belvarafenib 50mg QD Cobi 60mg QD	Belvarafenib 100mg BID Cobi 60mg QD		Belvarafenib 200mg QD Cobi 60mg QD	Belvarafenib 400 Cobi 60mg	00mg BID g QD
RelativeViability 1.00 0.75 0.50 0.25 0.00	RelativeViability The state of	Relative Viability 1.00 0.75 0.50 0.25 0.00	Relative Viability 1.00 0.75 0.50 0.25 0.00	RelativeViat 1.00 0.75 0.50 0.25 0.00	Relative Viability The property of the proper	-1233334 -334 -33-	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -3 -3 -3 -3 -3 -3 -3 -3	lativeViability 1.00 0.75 0.50 0.25 0.00 -3 PagRAFii Belvaratenih uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -1 -4 -3 -3 -2 -3 -3 -3 -3 -3 -3 -3	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -	Re la	elative Viability 1.00 0.75 0.50 0.25 0.00 -3 pagRAFi Belvarafenih uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	nanRAFi. Relyarafenih uM	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3 Page RAFi Belyarafenib IM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -	-4 -3 -2 nanRAFi Relvarafenih uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 - Page AFi. Relyada	RelativeViability 1.00 0.75 0.50 0.25 0.00
pankAFI_Belvaratenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	pankari_Belvaratenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	рапкагі_Beivaratenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QOD	pankAFI_Belvaratenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	pankari_Belvaratenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	panka-i_Belvaratenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	pankAFi_Belvaratenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD		рапкагт_вегvaratenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 40mg QD		pankAFi_Beivaratenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD		pankAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 60mg QD	panRAFi_Belvarai SK-MEL Belvarafenib 40 Cobi 60mg	L-30 Hoomg BID ng QD
HSA Excess 0.6 0.3 0.0 -0.3 -0.6	HSA Excess Who diplocated the second of the	HSA Excess 0.6 0.3 0.0 -0.3 -0.6	HSA Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 MEQUIPMORTHUM A DanRAFi Belvarafenih uM	HSA Exc O O O O O O O O O O O O O	Dess 1.3 WB Question HSA Excess 0.6 0.6 0.7 0.3 0.0 0.3 0.6	-1 -2 -3 -2 -1 DanRAFi Relvarafenih uM	HSA Excess 0.6 0.3 -0.6 -3 -3 DanRAFi Relivarafanih uM	HSA Excess 0.6 0.3 -0.3 -0.6 -0.3 -0.6 -3 -3 -4 -3 -2 panRAFi Rehearfeeib vM	HSA Excess 0.6 0.3 -0.6 -3 -4 -3 -2 pag A Fit Rehardtrails with	HSA Excess 0.6 0.3 -0.3 -0.6 -0.3 -0.6 -3 -4	panRAFi Belvarafenih uM	HSA Excess 0.6 0.3 ightharpoonup and a second properties of the second properties and a second properties are a second properties and a second properties are a second properties and a second properties and a second properties are a second properties and a second properties are a second properties and a second properties and a second properties are a second properties and a second properties are a second prop	HSA Excess 0.6 0.3 0.0 -0.3 -0.6 -0.6 -3 -4	DanRAFi Belvarafenih uM	HSA Excess 0.6 0.3 0.0 -0.3 -0.6 -3 -2 Depth ()	HSA Excess 0.6 0.3 10 10 10 10 10 10 10 10 10 1	-4 -3 -2 panRAFi Relvarafenih uM	HSA Excess 0.6 0.0 0.0 -0.3 WE WITH COPING THE PROPERTY OF THE PROPERTY O	HSA Excess 0.6 0.3 0.0 -0.3 -0.6
SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-30 Sk-mel-30 Belvarafenib 200mg QD Cobi 20mg QOD	SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	PALIKATI_BEIVARATENID UM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	pankarı_beivaratenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QD	pankAFi_Belvaratenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD		SK-MEL-30 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 40mg QD		panikAri_Belvaratenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD		рапканцыеlvaratenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 60mg QD	panRAFi_Belvar SK-MEL Belvarafenib 40 Cobi 60mg	L–30 H00mg BID ng QD
Bliss Excess 0.50 0.25 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.00 0.25 0.25 0.25 0.00 0.00 0.00	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.25 0.25 0.00 0.00 0.00 0.00 0.00	Bliss Exc o o o o o o o o o o o o o	Dess 1.50 Win qualified and 1.50 Min qualifie	-1 -2 -3 -2 -1 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 0.00 0.00 0.05 0.05 0.05	Bliss Excess 0.50 0.25	Bliss Excess 0.50 0.25 -0.25 -0.50 -0.25 -0.50 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -3 -	-3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 -0.25 -0.50 -0.50 -3 -2 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -3-	-3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.25 -0.25 -0.50 -3 -4 -3 -3 -3 -2 -4 -3 -3 -2 -4 -3 -3 -2 -4 -3 -3 -2 -4 -3 -3 -4 -3 -4 -3 -3 -4 -3 -3 -4 -4 -3 -3 -4 -4 -3 -3 -4 -4 -3 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4	Bliss Excess 0.50 0.25 0.25 -0.25 -0.50 -0.50 -3 -	-4 -3 -2 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.00 0.25 0.00 0.00 -0.25 -0.50 -3 -4 -3 panRAFi_Belvar	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50